Literature DB >> 16206168

Glutamate-mediated glial injury: mechanisms and clinical importance.

Carlos Matute1, María Domercq, María-Victoria Sánchez-Gómez.   

Abstract

Primary and/or secondary glial cell death can cause and/or aggravate human diseases of the central nervous system (CNS). Like neurons, glial cells are vulnerable to glutamate insults. Astrocytes, microglia, and oligodendrocytes express a wide variety of glutamate receptors and transporters that mediate many of the deleterious effects of glutamate. Astrocytes are responsible for most glutamate uptake in synaptic and nonsynaptic areas and consequently, are the major regulators of glutamate homeostasis. Microglia in turn may secrete cytokines, which can impair glutamate uptake and reduce the expression of glutamate transporters. Finally, oligodendrocytes, the myelinating cells of the CNS, are very sensitive to excessive glutamate signaling, which can lead to the apoptosis or necrosis of these cells. This review aims at summarizing the mechanisms leading to glial cell death as a consequence of alterations in glutamate signaling, and their clinical relevance. A thorough understanding of these events will undoubtedly lead to better therapeutic strategies to treat CNS diseases affecting glia and in particular, those that involve damage to white matter tracts. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16206168     DOI: 10.1002/glia.20275

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  105 in total

Review 1.  Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury.

Authors:  Dustin J Donnelly; Phillip G Popovich
Journal:  Exp Neurol       Date:  2007-06-30       Impact factor: 5.330

Review 2.  Neuroinflammation as a neurotoxic mechanism in alcoholism: commentary on "Increased MCP-1 and microglia in various regions of human alcoholic brain".

Authors:  Edith V Sullivan; Natalie M Zahr
Journal:  Exp Neurol       Date:  2008-07-14       Impact factor: 5.330

Review 3.  P2X7 receptors in oligodendrocytes: a novel target for neuroprotection.

Authors:  Carlos Matute
Journal:  Mol Neurobiol       Date:  2008-08-14       Impact factor: 5.590

4.  Decreased number and increased volume with mitochondrial enlargement of cerebellar synaptic terminals in a mouse model of chronic demyelination.

Authors:  Huy Bang Nguyen; Yang Sui; Truc Quynh Thai; Kazuhiro Ikenaka; Toshiyuki Oda; Nobuhiko Ohno
Journal:  Med Mol Morphol       Date:  2018-05-23       Impact factor: 2.309

Review 5.  Obstructive Sleep Apnoea and Hypertension: the Role of the Central Nervous System.

Authors:  Luke A Henderson; Vaughan G Macefield
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

6.  Acute oligodendrocyte loss with persistent white matter injury in a third trimester equivalent mouse model of fetal alcohol spectrum disorder.

Authors:  Jessie Newville; Carlos Fernando Valenzuela; Lu Li; Lauren L Jantzie; Lee Anna Cunningham
Journal:  Glia       Date:  2017-05-18       Impact factor: 7.452

Review 7.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

8.  Three-dimensional relationships between perisynaptic astroglia and human hippocampal synapses.

Authors:  Mark R Witcher; Yong D Park; Mark R Lee; Suash Sharma; Kristen M Harris; Sergei A Kirov
Journal:  Glia       Date:  2010-04       Impact factor: 7.452

Review 9.  Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders.

Authors:  Ebrahim Haroon; Andrew H Miller; Gerard Sanacora
Journal:  Neuropsychopharmacology       Date:  2016-09-15       Impact factor: 7.853

10.  Effects of oxygen-glucose deprivation on microglial mobility and viability in developing mouse hippocampal tissues.

Authors:  Ukpong Eyo; Michael E Dailey
Journal:  Glia       Date:  2012-07-28       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.